2024-10-21
参与CPHI Worldwide Milan 展会，展现公司
时间: 2023-08-10
来源: FireFox
作者: Operations Dept.
Novo Nordisk has been riding the momentum of weight loss drug Wegovy ever since it stormed onto the market in 2021, creating widespread hype and even some supply shortfalls. But, now, a cardio outcomes trial could seriously change the game for the burgeoning medicine.
In a large phase 3 trial, the drug cut the risk of major adverse cardiovascular events by 20% compared with placebo and standard of care, Novo said Tuesday. Specifically, investigators measured Wegovy's 2.4-mg dose for its ability to cut the risk of a cardio death, heart attack or stroke.
The trial enrolled 17,604 people and tested the drug for up to five years in people 45 and older who were overweight or obese and who had established cardiovascular disease. To be eligible for the trial, patients had to have had no history of diabetes.
Based on the trial win, Novo Nordisk said it expects to seek a label expansion to include the cardiovascular risk-reduction data in the U.S. and Europe yet this year. The company said the detailed results from the study, dubbed SELECT, will be presented at an upcoming scientific conference.
Investigators conducted the trial in 41 countries at more than 800 sites. The trial kicked off in 2018.
